1.20
전일 마감가:
$1.16
열려 있는:
$1.12
하루 거래량:
1.93M
Relative Volume:
1.19
시가총액:
$272.76M
수익:
-
순이익/손실:
$-179.82M
주가수익비율:
-0.9023
EPS:
-1.33
순현금흐름:
$-159.16M
1주 성능:
+15.38%
1개월 성능:
+34.11%
6개월 성능:
+72.51%
1년 성능:
+88.44%
Gossamer Bio Inc Stock (GOSS) Company Profile
명칭
Gossamer Bio Inc
전화
(858) 684-1300
주소
3115 MERRYFIELD ROW, SAN DIEGO, CA
GOSS을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
GOSS
Gossamer Bio Inc
|
1.20 | 236.39M | 0 | -179.82M | -159.16M | -1.33 |
![]()
ONC
Beigene Ltd Adr
|
241.43 | 27.03B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
436.00 | 112.64B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 40.86M | 0 | 0 | 0 | 0.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
588.34 | 64.17B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
VRNA
Verona Pharma Plc Adr
|
75.06 | 6.07B | 0 | -153.72M | -103.81M | -2.00 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-06-25 | 개시 | Oppenheimer | Outperform |
2024-04-05 | 재개 | Wedbush | Outperform |
2023-07-27 | 다운그레이드 | UBS | Buy → Neutral |
2023-03-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
2023-03-01 | 개시 | Guggenheim | Neutral |
2022-12-07 | 다운그레이드 | Barclays | Overweight → Equal Weight |
2022-12-07 | 다운그레이드 | JP Morgan | Neutral → Underweight |
2022-12-07 | 다운그레이드 | SMBC Nikko | Outperform → Neutral |
2022-10-20 | 개시 | Goldman | Buy |
2022-09-21 | 개시 | JP Morgan | Neutral |
2022-09-19 | 개시 | Wedbush | Outperform |
2022-04-18 | 개시 | Raymond James | Outperform |
2022-04-06 | 개시 | UBS | Buy |
2022-01-10 | 업그레이드 | SMBC Nikko | Neutral → Outperform |
2021-11-09 | 재개 | Cantor Fitzgerald | Overweight |
2021-09-21 | 재개 | Piper Sandler | Overweight |
2020-06-29 | 개시 | H.C. Wainwright | Buy |
2020-04-22 | 개시 | Piper Sandler | Overweight |
2020-02-27 | 개시 | Barclays | Overweight |
2019-12-03 | 재개 | BofA/Merrill | Buy |
2019-10-30 | 개시 | Berenberg | Buy |
2019-03-05 | 개시 | Barclays | Overweight |
2019-03-05 | 개시 | BofA/Merrill | Buy |
2019-03-05 | 개시 | Evercore ISI | Outperform |
2019-03-05 | 개시 | SVB Leerink | Outperform |
모두보기
Gossamer Bio Inc 주식(GOSS)의 최신 뉴스
Cantor Fitzgerald Forecasts Gossamer Bio FY2025 Earnings - Defense World
Analyze Gossamer Bio Inc (NASDAQ: GOSS) Before Investing. - Stocksregister
Price T Rowe Associates Inc. MD Has $59,000 Stock Holdings in Gossamer Bio, Inc. (NASDAQ:GOSS) - Defense World
Gossamer Bio, Inc. (NASDAQ:GOSS) Q1 2025 Earnings Call Transcript - MSN
Wedbush Reiterates “Outperform” Rating for Gossamer Bio (NASDAQ:GOSS) - Defense World
The Goldman Sachs Group Raises Gossamer Bio (NASDAQ:GOSS) Price Target to $8.00 - Defense World
GOSS Stock Update: Analyst Reiterates Outperform Rating | GOSS S - GuruFocus
Gossamer Bio’s Earnings Call: Mixed Sentiments and Strategic Moves - TipRanks
Gossamer Bio (GOSS): Goldman Sachs Raises Price Target to $8.00 - GuruFocus
Cantor Fitzgerald maintains Overweight on Gossamer Bio stock By Investing.com - Investing.com Nigeria
Cantor Fitzgerald maintains Overweight on Gossamer Bio stock - Investing.com
Earnings call transcript: Gossamer Bio exceeds Q1 2025 revenue forecasts By Investing.com - Investing.com Nigeria
Gossamer Bio: Q1 Earnings Snapshot - CT Insider
Gossamer Bio Inc (GOSS) Q1 2025 Earnings Call Highlights: Strategic Progress Amid Financial ... - Yahoo Finance
Gossamer Bio Inc (GOSS) Q1 2025 Earnings Call Highlights: Strate - GuruFocus
Transcript : Gossamer Bio, Inc., Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com
Earnings call transcript: Gossamer Bio exceeds Q1 2025 revenue forecasts - Investing.com Australia
Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Gossamer Bio earnings beat by $0.03, revenue topped estimates - Investing.com
Gossamer Bio Inc (GOSS) Q1 2025 Earnings: EPS Loss of $0.16 Beats Estimate, Revenue Surges to $9.9 Million - GuruFocus
GOSSAMER BIO Earnings Results: $GOSS Reports Quarterly Earnings - Nasdaq
Gossamer Bio (GOSS) Surpasses Revenue Estimates, Advances Key St - GuruFocus
Gossamer Bio (GOSS) Surpasses Revenue Estimates, Advances Key Studies | GOSS Stock News - GuruFocus
Gossamer Bio, Inc. SEC 10-Q Report - TradingView
Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study - Eagle-Tribune
Gossamer Bio Q1 2025 Earnings Call Transcript - MarketBeat
What To Expect From Gossamer Bio Inc (GOSS) Q1 2025 Earnings - GuruFocus
Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025 - Eagle-Tribune
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 7, 2025 - BioSpace
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rul - GuruFocus
Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference - The Joplin Globe
Market Highlights: Gossamer Bio Inc (GOSS) Ends on a Low Note at 1.09 - DWinneX
Gossamer Bio Inc: Is GOSS Stock Worth Buying? - Stocksregister
Gossamer Bio (GOSS) Expected to Announce Earnings on Tuesday - Defense World
Gossamer Bio: Initiating Hold As Late‐Stage Data Nears Inflection (GOSS) - Seeking Alpha
Selling Buzz: Gossamer Bio Inc [GOSS] Chief Medical Officer Aranda Richard sells 1,908 shares of the company - knoxdaily.com
Check out these key findings about Gossamer Bio Inc (GOSS) - Sete News
Geode Capital Management LLC Has $2.04 Million Stock Holdings in Gossamer Bio, Inc. (NASDAQ:GOSS) - Defense World
Was Gossamer Bio Inc (GOSS)’s session last reading good? - uspostnews.com
Gossamer Bio Inc (GOSS) Stock: A Year of Declines and Increases - investchronicle.com
Closing Strong: Gossamer Bio Inc (GOSS) Ends at 1.17, Up 0.86 from Last Close - DWinneX
Monitoring Gossamer Bio Inc (GOSS) after recent insider movements - knoxdaily.com
Gossamer Bio Inc (GOSS Stock: A Sea of Opportunity - investchronicle.com
Gossamer Bio Insider Confidence Rewarded, Stock Hits US$203m Market Cap - simplywall.st
3 Promising Penny Stocks With Market Caps Over $100M - simplywall.st
Taking the lead: Gossamer Bio Inc (GOSS) - Sete News
Oppenheimer initates Gossamer Bio Inc (GOSS) rating to an Outperform - knoxdaily.com
GOSS’s price-to-cash ratio: Is it a good investment at the moment? - uspostnews.com
Stock Performance Spotlight: Gossamer Bio Inc (GOSS) Ends the Day at 0.83, Up by 1.77 - DWinneX
Pleasing Signs As A Number Of Insiders Buy Gossamer Bio Stock - Yahoo Finance
The Goldman Sachs Group Has Lowered Expectations for Gossamer Bio (NASDAQ:GOSS) Stock Price - Defense World
Gossamer Bio Inc (GOSS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):